Pembrolizumab for advanced non-small cell lung cancer: immune cell study
Treatments studied
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This study is testing whether the immunotherapy drug pembrolizumab (Keytruda) works better for people with advanced non-small cell lung cancer by looking at their immune system's T-cells (a type of white blood cell). The goal is to understand which patients benefit most, which could help guide more personalized treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has spread (stage 4 or advanced) and is measurable by scans.
- You have not had any previous treatments for metastatic lung cancer (like chemotherapy or immunotherapy).
- You have not been treated before with a PD-1/PD-L1 inhibitor (e.g., Keytruda, Opdivo, Tecentriq).
- You must have a tumor sample from a biopsy (or be willing to provide one) that hasn't been irradiated, to study your immune system.
- You are generally able to do daily activities (ECOG 0-1) and your blood tests are within normal limits.
- You do NOT have a known targetable gene change (like EGFR or ALK) — this trial is for people without those mutations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial is testing whether a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) is effective for people with advanced non-small cell lung cancer. If you haven't had treatment yet and meet the health criteria, this study could offer a new option to control your cancer.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This study tests if the drug pembrolizumab (Keytruda), alone or with chemotherapy, works well for Black patients with advanced non-small cell lung cancer (NSCLC) who haven't had treatment yet. The goal is to see real-world results in this group.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.